Kos Bolsters Internal Sales Force To 1,000 Ahead Of New Launches
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will not renew a co-promotion agreement with Takeda for Niaspan and Advicor.
You may also be interested in...
Abbott Finds Lipid Lowering Partner With Kos Acquisition
Candidates would be competitors to Pfizer's Lipitor/torcetrapib combination.
Abbott Finds Lipid Lowering Partner With Kos Acquisition
Candidates would be competitors to Pfizer's Lipitor/torcetrapib combination.
Niacin Coverage Agreed To By CMS In Reversal Of Earlier Decision
CMS had originally determined niacin to be a vitamin and ineligible for coverage despite being a prescription product.